Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F.

Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, Fu H, Kozakov D, Vajda S, Pelletier J.

Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1046-51. doi: 10.1073/pnas.1011477108. Epub 2010 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6689.

2.

Homogenous time resolved fluorescence assay to identify modulators of cap-dependent translation initiation.

Cencic R, Yan Y, Pelletier J.

Comb Chem High Throughput Screen. 2007 Mar;10(3):181-8.

PMID:
17346117
4.
5.

Emerging therapeutics targeting mRNA translation.

Malina A, Mills JR, Pelletier J.

Cold Spring Harb Perspect Biol. 2012 Apr 1;4(4):a012377. doi: 10.1101/cshperspect.a012377.

6.

Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes.

Huang BP, Wang Y, Wang X, Wang Z, Proud CG.

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H505-14. doi: 10.1152/ajpheart.01105.2008. Epub 2008 Dec 12.

7.

Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication.

Cencic R, Desforges M, Hall DR, Kozakov D, Du Y, Min J, Dingledine R, Fu H, Vajda S, Talbot PJ, Pelletier J.

J Virol. 2011 Jul;85(13):6381-9. doi: 10.1128/JVI.00078-11. Epub 2011 Apr 20.

8.

c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.

Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J.

Cancer Res. 2008 Jul 1;68(13):5326-34. doi: 10.1158/0008-5472.CAN-07-5876. Erratum in: Cancer Res. 2008 Sep 1;68(17):7246.

9.
10.

Structural roles for human translation factor eIF3 in initiation of protein synthesis.

Siridechadilok B, Fraser CS, Hall RJ, Doudna JA, Nogales E.

Science. 2005 Dec 2;310(5753):1513-5.

12.

Targeting the eIF4F translation initiation complex for cancer therapy.

Konicek BW, Dumstorf CA, Graff JR.

Cell Cycle. 2008 Aug 15;7(16):2466-71. Epub 2008 Aug 18.

PMID:
18719377
13.
14.

Eukaryotic initiation factor 4F: a vulnerability of tumor cells.

Lee T, Pelletier J.

Future Med Chem. 2012 Jan;4(1):19-31. doi: 10.4155/fmc.11.150. Review.

PMID:
22168162
16.

Modulation of eukaryotic mRNA stability via the cap-binding translation complex eIF4F.

Ramirez CV, Vilela C, Berthelot K, McCarthy JE.

J Mol Biol. 2002 May 10;318(4):951-62.

PMID:
12054793
17.

Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.

Issaenko OA, Bitterman PB, Polunovsky VA, Dahlberg PS.

Cancer Gene Ther. 2012 Sep;19(9):609-18. doi: 10.1038/cgt.2012.39. Epub 2012 Jul 6.

18.
19.

Evidence for variation in the optimal translation initiation complex: plant eIF4B, eIF4F, and eIF(iso)4F differentially promote translation of mRNAs.

Mayberry LK, Allen ML, Dennis MD, Browning KS.

Plant Physiol. 2009 Aug;150(4):1844-54. doi: 10.1104/pp.109.138438. Epub 2009 Jun 3.

20.

Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.

Bitterman PB, Polunovsky VA.

Mol Cancer Ther. 2012 May;11(5):1051-61. doi: 10.1158/1535-7163.MCT-11-0530. Review.

Supplemental Content

Support Center